dc.contributor.author | Pranjol, MZI | |
dc.contributor.author | Zinovkin, DA | |
dc.contributor.author | Maskell, ART | |
dc.contributor.author | Stephens, LJ | |
dc.contributor.author | Achinovich, SL | |
dc.contributor.author | Los', DM | |
dc.contributor.author | Nadyrov, EA | |
dc.contributor.author | Hannemann, M | |
dc.contributor.author | Gutowski, NJ | |
dc.contributor.author | Whatmore, JL | |
dc.date.accessioned | 2019-07-12T12:50:31Z | |
dc.date.issued | 2019-07-03 | |
dc.description.abstract | Background:New treatment options for metastasised high-grade serous carcinoma (HGSC) are urgently needed. HGSC frequently metastasises to the omentum, inducing angiogenesis in the local omental microvasculature to facili-tate tumour growth. We previously showed that HGSC-secreted cathepsin L (CathL) induces pro-angiogenic changes in disease relevant human omental microvascular endothelial cells (HOMECs), suggesting a role in tumour angio-genesis. Here we investigate whether CathL acts by inducing local production of the carbohydrate-binding protein galectin-1 (Gal1), which has been reported to be involved in tumourigenesis in other tumours.
Methods:HOMECs were used for all experiments. Gal1 mRNA and protein levels were measured by RT-PCR and ELISA respectively. Gal1-induced cell proliferation was assessed using WST-1 assay, migration using a transwell assay and in vivo Gal1 expression by immunohistochemistry.
Results:CathL transcriptionally regulated HOMEC production and secretion of Gal1 via activation of NFκB (sig-nificantly inhibited by sulfasalazine). Gal1 significantly enhanced HOMEC migration (p < 0.001) and proliferation (p < 0.001), suggesting an autocrine action. The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 and PD98059 suggesting downstream activation of this pathway. Immunohistochemical analysis of omenta from HGSC patients with or without metastatic disease demonstrated a positive correlation between Gal1 expression and number of microvessels (r =0.8702, p < 0.001), and area of vessels (r =0.7283, p < 0.001), supporting a proangiogenic role for Gal1 in omental metastases.
Conclusion:HOMEC Gal1 transcription and release in response to CathL secreted from metastasising HGSC acts in an autocrine manner on the local microvasculature to induce pro-angiogenic changes, highlighting a potential new therapeutic target. | en_GB |
dc.description.sponsorship | FORCE Cancer Charity | en_GB |
dc.identifier.citation | Vol. 17 | en_GB |
dc.identifier.doi | 10.1186/s12967-019-1963-7 | |
dc.identifier.grantnumber | 50703 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/37968 | |
dc.language.iso | en | en_GB |
dc.publisher | BMC (Springer Nature) | en_GB |
dc.relation.url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473742400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0326ddbefd13eaffce8024ca57cffb07 | en_GB |
dc.rights | © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | en_GB |
dc.subject | Galectin-1 | en_GB |
dc.subject | Angiogenesis | en_GB |
dc.subject | Metastasis | en_GB |
dc.subject | High-grade serous carcinoma | en_GB |
dc.subject | Signalling pathways | en_GB |
dc.title | Cathepsin L-induced galectin-1 may act as a proangiogenic factor in the metastasis of high-grade serous carcinoma | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2019-07-12T12:50:31Z | |
dc.identifier.issn | 1479-5876 | |
exeter.article-number | ARTN 216 | en_GB |
dc.description | This is the author accepted manuscript. | en_GB |
dc.identifier.journal | Journal of translational medicine | en_GB |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
dcterms.dateAccepted | 2019-06-25 | |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2019-07-03 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2019-07-12T12:46:59Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2019-07-12T12:50:39Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2019-07-03 | |